Publications
Detailed Information
Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Seung-Heon | - |
dc.contributor.author | Kim, Yong Hwy | - |
dc.contributor.author | Kim, Jin Wook | - |
dc.contributor.author | Park, Chul-Kee | - |
dc.contributor.author | Jung, Hee-Won | - |
dc.contributor.author | Park, Sung-Hye | - |
dc.date.accessioned | 2012-05-31T00:22:01Z | - |
dc.date.available | 2012-05-31T00:22:01Z | - |
dc.date.issued | 2009-10 | - |
dc.identifier.citation | JOURNAL OF KOREAN NEUROSURGICAL SOCIETY; Vol.46 4; 385-388 | ko_KR |
dc.identifier.issn | 2005-3711 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76633 | - |
dc.description.abstract | Objective : We analyzed the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter in World Health Organization (WHO) grade III gliomas in association with other molecular markers to evaluate their prevalence. Methods : The samples of a total of 36 newly WHO grade III glioma patients including 19 anaplastic oligodendrogliomas (AO), 7 anaplastic oligoastrocytomas (AOA), and 10 anaplastic astrocytomas (AA) were analyzed. The methylation status of the MGMT gene promoter was confirmed by methylation-specific polymerase chain reaction. The 1p/19q chromosomal deletion status and EGFR amplification were assessed by Fluorescence In-Situ Hybridization. MGMT, EGFR, EGFRvIII, and p53 expression were analyzed by immunohistochemical staining. Results : The MGMT gene promoter was methylated in 32 (88.9%) and unmethylated in 4 (11.2%). Among them, all of the AO and AOA had methylated MGMT gene promoter without exception. Significant associations between MGMT gene promoter hypermethylation and 1p/19q deletion was observed (p = 0.003). Other molecular markers failed to show significant associations between MGMT gene promoter statuses. Conclusion : There was extensive epigenetic silencing of MGMT gene in high grade gliomas with oligodendroglial component. Together with frequent 1p/19q co-deletion in oligodendroglial tumors, this may add plausible explanations supporting the relative favorable prognosis in oligodendroglial tumors compared with pure astrocytic tumors. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN NEUROSURGICAL SOC | ko_KR |
dc.subject | MGMT gene promoter | ko_KR |
dc.subject | Methylation-specific PCR | ko_KR |
dc.subject | Oligodendroglioma | ko_KR |
dc.subject | Methylation | ko_KR |
dc.subject | 1p/19q | ko_KR |
dc.title | Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 양승훈 | - |
dc.contributor.AlternativeAuthor | 김용휘 | - |
dc.contributor.AlternativeAuthor | 김진욱 | - |
dc.contributor.AlternativeAuthor | 박철기 | - |
dc.contributor.AlternativeAuthor | 박성혜 | - |
dc.contributor.AlternativeAuthor | 정희원 | - |
dc.identifier.doi | 10.3340/jkns.2009.46.4.385 | - |
dc.citation.journaltitle | JOURNAL OF KOREAN NEUROSURGICAL SOCIETY | - |
dc.description.citedreference | Kuo LT, 2009, INT J CANCER, V124, P2872, DOI 10.1002/ijc.24303 | - |
dc.description.citedreference | Scheithauer BW, 2008, BRAIN PATHOL, V18, P307, DOI 10.1111/j.1750-3639.2008.00179.x | - |
dc.description.citedreference | van den Bent MJ, 2007, J NEUROPATH EXP NEUR, V66, P1074 | - |
dc.description.citedreference | Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4 | - |
dc.description.citedreference | Lavon I, 2007, CLIN CANCER RES, V13, P1429, DOI 10.1158/1078-0432.CCR-06-2050 | - |
dc.description.citedreference | Jeon YK, 2007, NEUROPATHOLOGY, V27, P10, DOI 10.1111/j.1440-1789.2006.00735.x | - |
dc.description.citedreference | Hegi ME, 2005, NEW ENGL J MED, V352, P997 | - |
dc.description.citedreference | Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575 | - |
dc.description.citedreference | Paz MF, 2004, CLIN CANCER RES, V10, P4933 | - |
dc.description.citedreference | Alonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7 | - |
dc.description.citedreference | Balana C, 2003, CLIN CANCER RES, V9, P1461 | - |
dc.description.citedreference | Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215 | - |
dc.description.citedreference | KLEIHUES P, 2002, J NEUROPATHOL EXP NE, V61, P226 | - |
dc.description.citedreference | Dong SM, 2001, J NEUROPATH EXP NEUR, V60, P808 | - |
dc.description.citedreference | Esteller M, 2000, NEW ENGL J MED, V343, P1350 | - |
dc.description.citedreference | Nutt CL, 2000, CANCER RES, V60, P4812 | - |
dc.description.citedreference | Esteller M, 1999, CANCER RES, V59, P793 | - |
dc.description.citedreference | KLEIHUES P, 1993, BRAIN PATHOL, V3, P255 | - |
dc.description.citedreference | PEGG AE, 1990, CANCER RES, V50, P6119 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.